Topical lidocaine and capsaicin 8% are the two topical options with the clearest evidence behind them for neuropathic foot pain, and which one fits depends on what is driving the neuropathy rather than on how the burning feels. An expert panel convened by the American Academy of Pain Medicine reported strong evidence and high consensus that capsaicin 8% is effective for diabetic peripheral neuropathy and for postherpetic neuralgia, and moderate evidence with high consensus that lidocaine is likely effective for diabetic peripheral neuropathy, idiopathic neuropathy and postsurgical neuropathy.1
The counterweight matters just as much. A Cochrane review of topical lidocaine in adults with chronic neuropathic pain found only 12 studies covering 508 participants in total, all judged at high risk of bias, and concluded that there was no good-quality randomized evidence to support its use.2 Topicals change the signal at the skin and nerve surface. They do not change what is damaging the nerve.
What to know before you try a topical
- Topicals modulate the signal, not the driver. The burning is an alarm, and the alarm keeps sounding while the underlying problem continues.
- The evidence is condition-specific. Support for lidocaine and for capsaicin 8% is attached to named diagnoses, not to “neuropathy” as a category.
- Peripheral neuropathy is a category, not a diagnosis. Metabolic, nutritional, autoimmune, toxic and structural drivers are often layered in the same patient.
- Testing changes decisions. On-site electrodiagnostic testing (EMG/NCS) helps establish which fibers are involved before a plan is built around a product.
What topical lidocaine does, and what it does not do
Lidocaine is a local anesthetic. Applied to the skin, it reduces the excitability of nerve endings under the area it covers, which can lower the intensity of burning or shooting pain in that patch of skin.
What it does not do is reach the cause. It does not improve flow through the small vessels that feed the nerve, correct a nutritional deficiency, or slow the metabolic chemistry that damaged the fiber in the first place.
Where the support is, and where it is not
The American Academy of Pain Medicine panel placed lidocaine’s strongest rating with postherpetic neuralgia, where it found strong evidence and high consensus that lidocaine is effective. For diabetic peripheral neuropathy, idiopathic neuropathy and postsurgical neuropathy the rating was moderate evidence with high consensus that lidocaine is likely effective.1
Read the Cochrane finding alongside that rather than instead of it. Twelve small trials in 508 adults is a thin evidence base, and thin evidence is a reason to set expectations carefully, not on its own a reason to rule out a low-risk option.2 Whether a prescription or over-the-counter topical belongs in your plan is a decision for your prescribing clinician.
Capsaicin 8% and when the diagnosis matches
Capsaicin works through a different pathway than lidocaine, and its labeled use is narrower. Qutenza (capsaicin 8% patch) is FDA-approved in adults only for neuropathic pain from postherpetic neuralgia and from diabetic peripheral neuropathy of the feet. Use for any other neuropathy driver is off-label, and it should be described that way before you agree to it.
The evidence rating tracks the label closely. The same expert panel found strong evidence and high consensus for capsaicin 8% in diabetic peripheral neuropathy and postherpetic neuralgia, and weaker ratings for other neuropathic pain conditions.1
What “applied in clinic” means
The capsaicin 8% patch is applied at Regenerve by a clinician. It is not dispensed for home use, and it is not repeated more often than every three months.
That spacing is part of how the treatment is designed, and it is one more reason the diagnosis has to be settled before the patch is scheduled. Our page on the Qutenza capsaicin 8% patch describes what the visit itself involves.
Why the driver decides what belongs in the plan
Patients often arrive with a list of creams, patches and counterirritants collected online. The list is not the problem. The problem is that it is organized around the sensation instead of around the cause, so two people with identical burning end up on identical products for entirely different diseases.
We work the other way around, starting from which driver is doing the most damage right now.
- Metabolic pattern. When the distribution and history fit diabetic peripheral neuropathy of the feet, both lidocaine and capsaicin 8% sit inside their evidence-supported and, for capsaicin 8%, FDA-labeled territory.
- Nutritional pattern. When the history points to B12 deficiency or a gluten-related process, a topical may make the nights easier while the actual correction happens elsewhere.
- Chemotherapy-related pattern. Symptom tools may still have a role, but the priority is understanding whether large fiber, small fiber or mixed involvement is present.
- Autoimmune or structural pattern. Topicals alone are the weakest choice here, because inflammation and impaired perfusion keep the nerve irritable regardless of what is on the skin.
Testing that changes the decision
Electrodiagnostic testing (EMG/NCS) is performed on site at Regenerve. It characterizes large-fiber conduction, which helps separate a systemic driver from a focal compression and tells us whether the symptom picture and the wiring picture agree.
Where unsteadiness or dizziness is also part of the story, VNG is available. VNG is a diagnostic test of inner-ear balance function, not a treatment, and it is used to find out whether the balance problem sits in the vestibular system rather than in the feet.
What to bring to your visit
Your clinician needs more than “it burns.” Pattern, timing and history are what narrow the list.
- Where it is: toes, forefoot, midfoot or the whole foot, and whether both sides are equally affected.
- When it is worst: particularly whether it wakes you at night.
- What it feels like: burning, tingling, electric shocks, numbness, or pain from light touch such as a bedsheet.
- Your history: diabetes or prediabetes, chemotherapy, alcohol use, celiac or gluten sensitivity, bariatric or other gastrointestinal surgery, known B12 status, and any toxic exposures.
- What has already been tested: prior EMG/NCS results and whether small fiber involvement has been raised.
Start with the Nerve Damage Score
The Nerve Damage Score is five questions, and it is free. It is designed to identify which driver is most likely doing the damage in your case, so the conversation about topicals starts from a diagnosis instead of a product list. We do not promise that nerve damage can be regenerated or reversed.
Regenerve, 4477 Woodson Rd #104, St. Louis, MO 63134. Call or text (314) 886-5902, or email info@regenerve.com. We are minutes from St. Louis Lambert International Airport and see patients from across the St. Louis region, Missouri and Illinois, including Edwardsville, Glen Carbon, Collinsville, Troy and Maryville.
Frequently asked questions
Is topical lidocaine worth trying for burning feet at night?
It is reasonable to discuss when your pain pattern matches a condition where lidocaine has support, and it carries little systemic risk. Treat it as symptom modulation and pair it with an evaluation of what is driving the burning, because the relief stops when the patch does. See why feet burn at night.
Does topical lidocaine help diabetic peripheral neuropathy of the feet?
The American Academy of Pain Medicine panel rated lidocaine as likely effective for diabetic peripheral neuropathy on moderate evidence with high consensus. It does not address the metabolic and microvascular injury underneath, which is where the rest of the plan goes. See diabetic peripheral neuropathy treatment in St. Louis.
Is the capsaicin 8% patch an option if my neuropathy is not diabetic?
Qutenza is FDA-approved in adults only for postherpetic neuralgia and for diabetic peripheral neuropathy of the feet, so any other driver is an off-label use and has to be discussed as such. It is applied in clinic by a clinician and repeated no more often than every three months. See the hidden drivers of peripheral neuropathy.
Why do topicals help less when I have small fiber neuropathy?
Small fiber involvement produces burning, hot-coal sensations and altered temperature perception that can be widespread rather than confined to the patch of skin a topical covers. Standard nerve conduction studies may also look normal, which is why the workup has to match the symptom pattern. See small fiber neuropathy symptoms and testing.
Should I get nerve testing before trying a topical?
Not necessarily before, but testing changes what comes after. Electrodiagnostic testing clarifies which fibers are affected, which narrows the list of likely drivers and tells us whether a topical is a bridge or a distraction. See treatment options for peripheral neuropathy in the feet.
Sources
- American Academy of Pain Medicine. Topical analgesics for neuropathic pain: an evidence-informed guide for the practicing clinician. Pain Medicine. 2026. AAPM clinical guideline summary
- Derry S, Wiffen PJ, Moore RA, Quinlan J. Topical lidocaine for neuropathic pain in adults. Cochrane Database of Systematic Reviews. 2014. PMID 25058164